Tags

Type your tag names separated by a space and hit enter

A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
Chem Biol Drug Des. 2009 Jan; 73(1):115-26.CB

Abstract

In this study, 3D-pharmacophore models of Aurora B kinase inhibitors have been developed by using HipHop and HypoGen modules in Catalyst software package. The best pharmacophore model, Hypo1, which has the highest correlation coefficient (0.9911), consists of one hydrogen-bond acceptor, one hydrogen-bond donor, one hydrophobic aliphatic moiety and one ring aromatic feature. Hypo1 was validated by test set and cross-validation methods. And the specificity of Hypo1 to Aurora B inhibitors was examined with the use of selective inhibitors against Aurora B and its paralogue Aurora A. The results clearly indicate that Hypo1 can differentiate selective inhibitors of Aurora B from those of Aurora A, and the ring aromatic feature likely plays some important roles for the specificity of Hypo1. Then Hypo1 was used as a 3D query to screen several databases including Specs, NCI, Maybridge and Chinese Nature Product Database (CNPD) for identifying new inhibitors of Aurora B. The hit compounds were subsequently subjected to filtering by Lipinski's rule of five and docking studies to refine the retrieved hits, and some compounds selected from the top ranked hits have been suggested for further experimental assay studies.

Authors+Show Affiliations

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19152640

Citation

Wang, Hui-Yuan, et al. "A Specific Pharmacophore Model of Aurora B Kinase Inhibitors and Virtual Screening Studies Based On It." Chemical Biology & Drug Design, vol. 73, no. 1, 2009, pp. 115-26.
Wang HY, Li LL, Cao ZX, et al. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it. Chem Biol Drug Des. 2009;73(1):115-26.
Wang, H. Y., Li, L. L., Cao, Z. X., Luo, S. D., Wei, Y. Q., & Yang, S. Y. (2009). A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it. Chemical Biology & Drug Design, 73(1), 115-26. https://doi.org/10.1111/j.1747-0285.2008.00751.x
Wang HY, et al. A Specific Pharmacophore Model of Aurora B Kinase Inhibitors and Virtual Screening Studies Based On It. Chem Biol Drug Des. 2009;73(1):115-26. PubMed PMID: 19152640.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it. AU - Wang,Hui-Yuan, AU - Li,Lin-Li, AU - Cao,Zhi-Xing, AU - Luo,Shi-Dong, AU - Wei,Yu-Quan, AU - Yang,Sheng-Yong, PY - 2009/1/21/entrez PY - 2009/1/21/pubmed PY - 2009/2/20/medline SP - 115 EP - 26 JF - Chemical biology & drug design JO - Chem Biol Drug Des VL - 73 IS - 1 N2 - In this study, 3D-pharmacophore models of Aurora B kinase inhibitors have been developed by using HipHop and HypoGen modules in Catalyst software package. The best pharmacophore model, Hypo1, which has the highest correlation coefficient (0.9911), consists of one hydrogen-bond acceptor, one hydrogen-bond donor, one hydrophobic aliphatic moiety and one ring aromatic feature. Hypo1 was validated by test set and cross-validation methods. And the specificity of Hypo1 to Aurora B inhibitors was examined with the use of selective inhibitors against Aurora B and its paralogue Aurora A. The results clearly indicate that Hypo1 can differentiate selective inhibitors of Aurora B from those of Aurora A, and the ring aromatic feature likely plays some important roles for the specificity of Hypo1. Then Hypo1 was used as a 3D query to screen several databases including Specs, NCI, Maybridge and Chinese Nature Product Database (CNPD) for identifying new inhibitors of Aurora B. The hit compounds were subsequently subjected to filtering by Lipinski's rule of five and docking studies to refine the retrieved hits, and some compounds selected from the top ranked hits have been suggested for further experimental assay studies. SN - 1747-0285 UR - https://www.unboundmedicine.com/medline/citation/19152640/A_specific_pharmacophore_model_of_Aurora_B_kinase_inhibitors_and_virtual_screening_studies_based_on_it_ L2 - https://doi.org/10.1111/j.1747-0285.2008.00751.x DB - PRIME DP - Unbound Medicine ER -